Apollo Endosurgery Stock Forecast, Price & News

Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions

Is Apollo Endosurgery a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Apollo Endosurgery stock.
View analyst ratings for Apollo Endosurgery or view top-rated stocks.

How has Apollo Endosurgery's stock been impacted by COVID-19?

Apollo Endosurgery's stock was trading at $2.0650 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, APEN stock has increased by 186.2% and is now trading at $5.91.
View which stocks have been most impacted by COVID-19.

Are investors shorting Apollo Endosurgery?

Apollo Endosurgery saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 842,400 shares, an increase of 38.4% from the December 15th total of 608,700 shares. Based on an average daily volume of 288,900 shares, the days-to-cover ratio is currently 2.9 days. Currently, 5.3% of the company's shares are sold short.
View Apollo Endosurgery's Short Interest.

When is Apollo Endosurgery's next earnings date?

Apollo Endosurgery is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Apollo Endosurgery.

How were Apollo Endosurgery's earnings last quarter?

Apollo Endosurgery, Inc. (NASDAQ:APEN) released its quarterly earnings data on Sunday, October, 31st. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.28) by $0.05. The biotechnology company had revenue of $16.35 million for the quarter, compared to analysts' expectations of $16.20 million. Apollo Endosurgery had a negative trailing twelve-month return on equity of 589.59% and a negative net margin of 29.80%. During the same quarter last year, the business earned ($0.11) EPS.
View Apollo Endosurgery's earnings history.

What guidance has Apollo Endosurgery issued on next quarter's earnings?

Apollo Endosurgery issued an update on its FY 2021 earnings guidance on Thursday, November, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $63 million-$64 million, compared to the consensus revenue estimate of $62.72 million.

What price target have analysts set for APEN?

5 brokers have issued twelve-month price objectives for Apollo Endosurgery's shares. Their forecasts range from $12.00 to $15.00. On average, they anticipate Apollo Endosurgery's share price to reach $13.60 in the next twelve months. This suggests a possible upside of 130.1% from the stock's current price.
View analysts' price targets for Apollo Endosurgery or view top-rated stocks among Wall Street analysts.

Who are Apollo Endosurgery's key executives?

Apollo Endosurgery's management team includes the following people:

• Charles S. McKhann, President, Chief Executive Officer & Director
• John Molesphini, Executive Vice President-Operations
• Jeffrey G. Black, Chief Financial Officer (LinkedIn Profile)
• Christopher J. Gostout, Chief Medical Officer
• Tiffanie Gilbreth, Vice President-Clinical & Medical Affairs

Who are some of Apollo Endosurgery's key competitors?

Some companies that are related to Apollo Endosurgery include Surmodics (SRDX), Orthofix Medical (OFIX), OraSure Technologies (OSUR), Antares Pharma (ATRS), TransEnterix (TRXC), MiMedx Group (MDXG), Invo Bioscience (IVOB), UFP Technologies (UFPT), Nyxoah (NYXH), IRadimed (IRMD), Anika Therapeutics (ANIK), SeaSpine (SPNE), Vapotherm (VAPO), Apyx Medical (APYX) and Accuray (ARAY).
View all of APEN's competitors.

What other stocks do shareholders of Apollo Endosurgery own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), OPKO Health (OPK), Pfizer (PFE), Sunesis Pharmaceuticals (SNSS), Biocept (BIOC), Co-Diagnostics (CODX) and Second Sight Medical Products (EYES).

What is Apollo Endosurgery's stock symbol?

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

How do I buy shares of Apollo Endosurgery?

Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apollo Endosurgery's stock price today?

One share of APEN stock can currently be purchased for approximately $5.91.

How much money does Apollo Endosurgery make?

Apollo Endosurgery has a market capitalization of $169.63 million and generates $42.05 million in revenue each year. The biotechnology company earns $-22.61 million in net income (profit) each year or ($0.65) on an earnings per share basis.

How many employees does Apollo Endosurgery have?

Apollo Endosurgery employs 158 workers across the globe.

What is Apollo Endosurgery's official website?

The official website for Apollo Endosurgery is www.apolloendo.com.

Where are Apollo Endosurgery's headquarters?

Apollo Endosurgery is headquartered at 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746.

How can I contact Apollo Endosurgery?

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at (512) 279-5100, via email at [email protected], or via fax at 858-678-0900.